Fatty liver disease affects approximately one in three UK adults, yet many people wonder whether this common condition can lead to dangerous complications such as elevated ammonia levels. Ammonia is a toxic by-product of protein metabolism that healthy livers efficiently convert into harmless urea. Whilst simple fatty liver disease (hepatic steatosis) typically does not cause high ammonia levels, understanding the relationship between liver disease progression and ammonia metabolism is crucial. This article examines when and how fatty liver disease might affect ammonia levels, the warning signs to recognise, and the importance of early intervention to prevent serious complications such as hepatic encephalopathy.
Summary: Simple fatty liver disease does not typically cause elevated ammonia levels; high ammonia occurs only when the condition progresses to advanced cirrhosis with significant loss of liver function.
- Healthy livers convert toxic ammonia into urea through the urea cycle; early-stage fatty liver disease maintains this function effectively.
- Elevated ammonia (hyperammonaemia) develops when fatty liver progresses to cirrhosis, reducing functioning liver cells and impairing detoxification capacity.
- High ammonia causes hepatic encephalopathy, presenting with confusion, personality changes, tremor, and in severe cases, stupor or coma.
- Blood ammonia levels typically remain normal (11–32 μmol/L) in uncomplicated fatty liver disease; testing is reserved for suspected encephalopathy.
- Treatment for elevated ammonia includes lactulose to reduce ammonia production and rifaximin to decrease ammonia-producing gut bacteria.
- Sudden confusion or altered consciousness in someone with liver disease requires emergency medical assessment via 999 or A&E attendance.
Table of Contents
Am I eligible for weight loss injections?
Find out whether you might be eligible!
Answer a few quick questions to see whether you may be suitable for prescription weight loss injections (like Wegovy® or Mounjaro®).
- No commitment — just a quick suitability check
- Takes about 1 minute to complete
Understanding Fatty Liver Disease and Ammonia Metabolism
Fatty liver disease, medically termed hepatic steatosis, occurs when excess fat accumulates within liver cells. This condition exists in two primary forms: non-alcoholic fatty liver disease (NAFLD), which affects individuals who consume little to no alcohol, and alcohol-related liver disease (ARLD), resulting from excessive alcohol intake. NAFLD has become increasingly prevalent in the UK, affecting approximately one in three adults according to NHS estimates, often associated with obesity, type 2 diabetes, and metabolic syndrome.
The liver plays a crucial role in ammonia metabolism through a process called the urea cycle. Ammonia is a toxic by-product of protein breakdown that occurs naturally in the body, particularly in the intestines where gut bacteria break down dietary proteins and amino acids. Healthy liver cells convert this ammonia into urea, a less toxic compound that can be safely excreted through urine. This detoxification process is essential for maintaining normal brain and body function.
In early-stage fatty liver disease (simple steatosis), the liver typically maintains adequate function despite fat accumulation. The hepatocytes (liver cells) continue to perform their metabolic duties, including ammonia detoxification, relatively efficiently. However, when fatty liver disease progresses to non-alcoholic steatohepatitis (NASH)—characterised by inflammation and liver cell injury—chronic inflammation and oxidative stress develop within the liver tissue.
When fatty liver disease advances further to cirrhosis, the liver's architecture becomes disrupted. Inflammation leads to fibrosis (scarring), which impairs blood flow and reduces the number of functioning hepatocytes. This progressive damage can eventually compromise the liver's ability to detoxify ammonia effectively, though this typically occurs only in advanced disease stages with significant loss of liver function.
Can Fatty Liver Cause High Ammonia Levels?
Simple fatty liver disease (hepatic steatosis) alone does not typically cause elevated ammonia levels. In the early stages of NAFLD or ARLD, liver function remains largely preserved, and the organ continues to metabolise ammonia efficiently through the urea cycle. Blood ammonia levels in patients with uncomplicated fatty liver disease generally remain within normal reference ranges (typically 11–32 μmol/L in adults, though reference ranges vary between laboratories).
However, there is a recognised link between advanced liver disease and hyperammonaemia (elevated blood ammonia). When fatty liver disease progresses to cirrhosis—characterised by extensive scarring and loss of functional liver tissue—the capacity for ammonia detoxification becomes significantly impaired. In cirrhotic patients, several mechanisms contribute to ammonia accumulation:
-
Reduced hepatocyte mass: Fewer functioning liver cells are available to convert ammonia to urea
-
Portosystemic shunting: Abnormal blood vessels develop that bypass the liver, allowing ammonia-rich blood from the intestines to enter systemic circulation without detoxification
-
Impaired urea cycle function: Damaged hepatocytes cannot efficiently perform the enzymatic reactions required for ammonia metabolism
It is important to recognise that elevated ammonia can also result from other causes, including gastrointestinal bleeding, renal failure, certain medications (such as sodium valproate), urease-producing infections, transjugular intrahepatic portosystemic shunt (TIPS) procedures, and rare inherited urea cycle defects. These factors may act as precipitants in patients with underlying liver disease or occur independently.
The progression from simple steatosis to cirrhosis typically occurs over many years or decades. Estimates suggest that approximately 10–20% of patients with NASH may develop cirrhosis over time, though this varies considerably based on individual risk factors including diabetes, obesity, and ongoing liver injury.
It is important to emphasise that fatty liver disease must reach advanced stages with significant functional impairment before ammonia levels become clinically elevated. Patients with early-stage fatty liver disease should not assume they have hyperammonaemia, as this complication is associated specifically with decompensated liver disease or cirrhosis. Regular monitoring and lifestyle modifications can often prevent progression to these advanced stages.
Symptoms and Warning Signs of Elevated Ammonia
Elevated ammonia levels primarily affect the central nervous system, leading to a condition called hepatic encephalopathy (HE). This neuropsychiatric syndrome occurs when toxic substances, particularly ammonia, accumulate in the bloodstream and cross the blood-brain barrier, interfering with normal brain function. It is important to note that hepatic encephalopathy is primarily a clinical diagnosis based on symptoms and examination findings; blood ammonia levels do not always correlate with symptom severity.
Early symptoms of hepatic encephalopathy may be subtle and include:
-
Mild confusion or difficulty concentrating
-
Changes in sleep patterns (sleeping during the day, wakefulness at night)
-
Personality changes or mood alterations
-
Forgetfulness or impaired short-term memory
-
Slowed thinking or response times
-
Subtle tremor, particularly a characteristic "flapping tremor" (asterixis) of the hands
As the condition progresses, more severe neurological symptoms develop:
-
Marked confusion and disorientation
-
Inappropriate behaviour or agitation
-
Slurred speech
-
Significant drowsiness or lethargy
-
Difficulty with coordination and balance
-
In severe cases, stupor or coma
Patients with advanced liver disease may also experience other symptoms related to hepatic decompensation, including jaundice (yellowing of skin and eyes), ascites (abdominal fluid accumulation), easy bruising or bleeding, and peripheral oedema (leg swelling). These signs indicate significant liver dysfunction and warrant urgent medical assessment.
It is crucial to note that hepatic encephalopathy represents a medical emergency when symptoms are moderate to severe. Family members or carers may notice changes before the patient recognises them, as insight can be impaired. Any sudden change in mental status, particularly in someone with known liver disease, requires immediate medical evaluation. The NHS advises that confusion, drowsiness, or altered consciousness in the context of liver disease should prompt urgent contact with healthcare services or attendance at an emergency department.
Diagnosis and Testing for Liver Function and Ammonia Levels
Diagnosing fatty liver disease and assessing its impact on liver function involves a comprehensive approach combining clinical assessment, blood tests, and imaging studies. Initial evaluation typically begins with a thorough medical history and physical examination by a GP or hepatologist.
Blood tests form the cornerstone of liver function assessment:
-
Liver function tests (LFTs): Measure enzymes such as alanine aminotransferase (ALT), aspartate aminotransferase (AST), alkaline phosphatase (ALP), and bilirubin. Elevated transaminases may indicate liver inflammation, though levels can be normal in simple steatosis and even in advanced fibrosis or cirrhosis.
-
Albumin and prothrombin time/INR: Assess the liver's synthetic function; reduced albumin or prolonged clotting times suggest significant hepatic impairment.
-
Blood ammonia levels: May be measured when hepatic encephalopathy is suspected, though HE is primarily a clinical diagnosis. Venous samples must be processed rapidly, as ammonia levels can rise artificially if delayed. Reference ranges vary between laboratories (typically 11–32 μmol/L). Importantly, ammonia levels correlate poorly with the severity of hepatic encephalopathy and are not routinely required to diagnose or grade the condition.
Imaging investigations help characterise liver disease:
-
Ultrasound scanning: First-line imaging to detect hepatic steatosis, assess liver texture, and identify complications such as portal hypertension
-
Transient elastography (FibroScan): Non-invasive assessment of liver stiffness to quantify fibrosis and fat content
-
CT or MRI scanning: May be used for detailed assessment when ultrasound is inconclusive
According to NICE guidance (NG49), patients with suspected NAFLD should undergo risk stratification using validated scoring systems. The recommended pathway includes:
- Initial assessment with the NAFLD Fibrosis Score or FIB-4 index, which combine age, BMI, and blood test results to estimate fibrosis risk
- For those at increased risk, Enhanced Liver Fibrosis (ELF) blood test to further assess fibrosis severity
- Patients with ELF scores ≥10.51 (indicating advanced fibrosis) should be referred to specialist hepatology services for further assessment, which may include liver biopsy—the gold standard for staging liver disease
When hepatic encephalopathy is suspected, management focuses on identifying and treating precipitating factors—such as infection, gastrointestinal bleeding, constipation, dehydration, electrolyte disturbances, or medication effects (for example benzodiazepines or opioids). Specialist assessment may occasionally include psychometric testing or electroencephalography (EEG) to evaluate minimal or covert hepatic encephalopathy, though these are not routine first-line investigations for overt HE.
Treatment and Management Options
Management strategies for fatty liver disease and elevated ammonia levels differ significantly depending on disease stage and severity. For early-stage fatty liver disease, treatment focuses on addressing underlying risk factors and preventing progression.
Lifestyle modifications represent first-line management for NAFLD:
-
Weight loss: A reduction of 7–10% of body weight can significantly improve liver inflammation and fibrosis. NICE recommends structured weight management programmes combining dietary changes with increased physical activity.
-
Dietary changes: Adopting a Mediterranean-style diet rich in vegetables, fruits, whole grains, and healthy fats whilst limiting processed foods, refined sugars, and saturated fats.
-
Exercise: At least 150 minutes of moderate-intensity aerobic activity weekly, which improves insulin sensitivity and reduces hepatic fat content.
-
Alcohol: Complete abstinence is essential for alcohol-related liver disease. For NAFLD, UK Chief Medical Officers advise staying within low-risk drinking limits (not regularly exceeding 14 units per week, spread over 3 or more days). Abstinence is recommended for patients with advanced fibrosis or cirrhosis.
Medical management of associated conditions:
-
Optimising control of type 2 diabetes, hypertension, and dyslipidaemia
-
Certain medications, such as pioglitazone or vitamin E, may be considered by specialists in selected patients with biopsy-proven NASH. These are off-label uses in the UK and require careful risk–benefit discussion, including consideration of potential adverse effects (for example weight gain and heart failure risk with pioglitazone; concerns with long-term high-dose vitamin E).
-
Regular medication review to discontinue potentially hepatotoxic drugs
For patients with elevated ammonia levels and hepatic encephalopathy, specific treatments include:
-
Lactulose: A synthetic disaccharide that acidifies the colon, reducing ammonia production and absorption. Dosing is adjusted to achieve 2–3 soft bowel movements daily. Lactulose is licensed in the UK for the treatment of portal-systemic/hepatic encephalopathy.
-
Rifaximin: A non-absorbable antibiotic that reduces ammonia-producing gut bacteria. Rifaximin 550 mg is licensed in the UK and recommended by NICE (TA337) for the prevention of recurrent episodes of overt hepatic encephalopathy, typically used in combination with lactulose after an initial episode.
-
Identifying and treating precipitants: Addressing infections, correcting electrolyte imbalances, managing constipation, and reviewing medications that may worsen encephalopathy (such as benzodiazepines or opioids).
-
Nutritional support: Ensuring adequate protein intake—current evidence supports 1.2–1.5 g/kg body weight per day in patients with cirrhosis, contrary to outdated advice to restrict protein. A late-evening snack may help reduce overnight fasting. Branched-chain amino acid (BCAA) supplementation may be considered by specialists in selected patients, though evidence is limited.
Patients with decompensated cirrhosis and recurrent hepatic encephalopathy require specialist hepatology input and may need evaluation for liver transplantation, which offers the only definitive cure for end-stage liver disease. Transplant assessment considers multiple factors including disease severity, overall health status, and absence of contraindications.
Reporting side effects: If you experience any side effects from prescribed medications, you should report them to your doctor or pharmacist. You can also report suspected side effects directly via the MHRA Yellow Card scheme at www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store.
When to Seek Medical Advice
Understanding when to seek medical attention is crucial for patients with fatty liver disease or those at risk of liver-related complications. Different scenarios warrant varying levels of urgency in accessing healthcare services.
Routine GP consultation is appropriate if you:
-
Have risk factors for fatty liver disease (obesity, type 2 diabetes, metabolic syndrome) and wish to be screened
-
Experience persistent fatigue, vague abdominal discomfort, or unexplained weight changes
-
Have abnormal liver function tests detected during routine blood work
-
Have been diagnosed with fatty liver disease and require ongoing monitoring
-
Notice gradual changes in your health that concern you
Your GP can arrange appropriate investigations, provide lifestyle advice, and refer you to specialist services if needed. NICE recommends that patients with NAFLD and evidence of advanced fibrosis (for example ELF score ≥10.51) should be referred to hepatology services for specialist assessment and management.
Urgent same-day medical assessment is necessary if you develop:
-
Jaundice (yellowing of the skin or whites of the eyes)
-
Significant abdominal swelling or pain
-
Vomiting blood or passing black, tarry stools
-
Easy bruising or bleeding that doesn't stop
-
Persistent nausea and vomiting
Emergency medical attention (call 999 or attend A&E immediately) is required if you or someone you know experiences:
-
Sudden confusion, disorientation, or altered consciousness
-
Severe drowsiness or difficulty staying awake
-
Seizures
-
Vomiting large amounts of blood
-
Signs of severe infection with known liver disease (fever, rigors, rapid deterioration)
For patients with known liver disease, maintaining regular follow-up appointments is essential. Contact your hepatology team or GP promptly if you notice any change in symptoms, new medication side effects, or concerns about disease progression. Early intervention can prevent complications and improve outcomes.
Family members and carers should be vigilant for subtle personality changes, confusion, or altered sleep patterns in loved ones with liver disease, as patients may lack insight into early hepatic encephalopathy. The NHS 111 service can provide advice if you're unsure whether symptoms require urgent attention, though err on the side of caution with neurological symptoms or signs of liver decompensation.
Frequently Asked Questions
At what stage does fatty liver disease start causing high ammonia levels?
Fatty liver disease causes elevated ammonia levels only when it progresses to advanced cirrhosis with significant liver scarring and loss of functioning liver cells. Simple fatty liver (steatosis) and even early-stage inflammation (NASH) typically maintain normal ammonia metabolism, as the liver continues to convert ammonia to urea efficiently through the urea cycle.
What are the first signs that my ammonia levels might be too high?
Early signs of elevated ammonia include mild confusion, difficulty concentrating, changes in sleep patterns (daytime sleepiness, night-time wakefulness), personality changes, forgetfulness, and a characteristic flapping tremor of the hands called asterixis. These symptoms indicate hepatic encephalopathy and require prompt medical assessment, particularly if you have known liver disease.
Can I have normal liver blood tests but still have high ammonia from fatty liver?
It is highly unlikely to have elevated ammonia with normal liver function if fatty liver is the only cause, as hyperammonaemia from liver disease requires advanced cirrhosis with significant functional impairment. Liver function tests (albumin, clotting times) typically show abnormalities before ammonia rises, though transaminases can occasionally be normal even in cirrhosis.
How is fatty liver disease different from cirrhosis when it comes to ammonia?
Fatty liver disease involves fat accumulation in liver cells but maintains adequate liver function and normal ammonia metabolism, whilst cirrhosis represents advanced scarring with reduced functioning liver tissue that cannot efficiently detoxify ammonia. The progression from fatty liver to cirrhosis typically takes many years or decades, and only 10–20% of patients with inflammatory NASH eventually develop cirrhosis.
Should I ask my GP to test my ammonia levels if I have been diagnosed with fatty liver?
Routine ammonia testing is not necessary for uncomplicated fatty liver disease, as levels remain normal in early-stage disease and the test is reserved for suspected hepatic encephalopathy. Your GP will monitor liver function through standard blood tests (LFTs, albumin, clotting) and assess fibrosis risk using scoring systems; ammonia testing becomes relevant only if you develop confusion or neurological symptoms suggesting advanced liver disease.
What happens if my fatty liver progresses and my ammonia gets too high?
If fatty liver progresses to cirrhosis with elevated ammonia, you may develop hepatic encephalopathy requiring treatment with lactulose (to reduce ammonia production) and rifaximin (to decrease ammonia-producing gut bacteria). Severe cases with confusion or altered consciousness require emergency hospital admission, and recurrent episodes may necessitate specialist hepatology assessment for potential liver transplantation evaluation.
The health-related content published on this site is based on credible scientific sources and is periodically reviewed to ensure accuracy and relevance. Although we aim to reflect the most current medical knowledge, the material is meant for general education and awareness only.
The information on this site is not a substitute for professional medical advice. For any health concerns, please speak with a qualified medical professional. By using this information, you acknowledge responsibility for any decisions made and understand we are not liable for any consequences that may result.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Heading 6
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur.
Block quote
Ordered list
- Item 1
- Item 2
- Item 3
Unordered list
- Item A
- Item B
- Item C
Bold text
Emphasis
Superscript
Subscript
